Match each disease-modifying antirheumatic drug (DMARD) or immunosuppressive agent to its most characteristic adverse effect or required screening protocol.
- HydroxychloroquineIrreversible macular toxicity requiring periodic ophthalmologic evaluations
- EtanerceptReactivation of latent tuberculosis requiring pretreatment screening with an interferon-gamma release assay
- MethotrexateHepatotoxicity, stomatitis, and cytopenias that can be mitigated by concurrent folic acid administration
- CyclophosphamideHemorrhagic cystitis and increased risk of bladder transitional cell carcinoma
Cevap
Hydroxychloroquine matches with macular toxicity; Etanercept matches with latent tuberculosis reactivation; Methotrexate matches with hepatotoxicity and cytopenias; Cyclophosphamide matches with hemorrhagic cystitis.
Each immunosuppressive medication has a unique toxicity profile that dictates specific pre-treatment screening and ongoing monitoring. Safe long-term management of rheumatologic diseases requires pairing the drug with its classic adverse effect.
Adım Adım Çözüm
Anahtar Kavram
Pharmacologic adverse effects and required monitoring for disease-modifying antirheumatic drugs (DMARDs)
Tahmini Süre:1m 30s